Sarcoidosis Therapeutics Market : Analysis and Research Report by Experts 2026

Posted by Rohini Chaudhari on July 3rd, 2019

Sarcoidosis is a rare inflammatory disease characterized by the development of tiny lumps of cells in organs throughout the body. It is also known as Besnier-Boeck-Schaumann disease. The lumps are called granulomas. Granulomas can occur in the lymph nodes, skin, eyes, or other areas of the body; however, these mostly occur in the lungs. The cause of sarcoidosis is unclear. The disease can affect people of all ages, sex, and race. It is more common in African Americans and in people with Irish, German, Asian, Scandinavian, and Puerto Rican origin. Sarcoidosis appears most often in people aged between 20 and 40. It is not a contagious disease. It is estimated that only 30% of sarcoidosis patients develop chronic disease. In majority of cases, the disease can be cured within one or two years. Many people with sarcoidosis do not have any symptoms. Others have only vague symptoms such as night sweats, depression, sleep problems, loss of appetite, weight loss, and fever.

Report Overview @

Sarcoidosis affects people of all ages across the world. Globally, women are more affected than men. The highest annual incidence has been observed in countries in Northern Europe at 5 to 40 cases per 100,000 people per year. African Americans are 3 times more likely to have sarcoidosis than Caucasian Americans.

The global sarcoidosis therapeutics market is expected to be driven by research undertaking and funding to control the rising prevalence of sarcoidosis. For instance, the National Institutes of Health (NIH) granted US$ 8.3 Mn to the University of Pittsburgh to explore the relationship between gene activation process, sarcoidosis disease progression, and lung bacteria. Other major trends in global sarcoidosis therapeutics include strategic alliances. Pharma companies are working together or with research organizations to develop medications for the treatment of sarcoidosis. In March 2015, THERAMetrics Holding AG signed collaboration and licensing agreement with Centurion Pharma to develop and commercialize Aviptadil for sarcoidosis. In December 2018, aTyr Pharma announced collaboration with Foundation for Sarcoidosis Research (FSR) for assistance in clinical trial site initiation and patient enrollment for pulmonary sarcoidosis. Institutions and organizations are spreading awareness about sarcoidosis among people. In the U.K., the British Lung Foundation (BLF) is creating awareness about the early diagnosis and therapeutics of sarcoidosis.

Request Brochure @

The global sarcoidosis therapeutics market can be segmented based on therapy and route of administration. In terms of therapy, the global sarcoidosis therapeutics market can be categorized into immunosuppressant drugs, tumor necrosis factor alpha (TNF-α) blockers, corticosteroids, and others. Prednisone is the most common corticosteroid prescribed for sarcoidosis. Immunosuppressant drugs such as methotrexate could be given to people who are unable to take corticosteroids. Based on route of administration, the global sarcoidosis therapeutics market can be classified into intravenous, oral, subcutaneous, and inhalation. Inhaled corticosteroids are used to treat lung-related symptoms of sarcoidosis.

In terms of region, the global sarcoidosis therapeutics market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is projected to lead the global sarcoidosis therapeutics market during the forecast period. The region’s dominance is attributed to industry and academia partnership and funding to encourage more research on sarcoidosis and research undertaken by various pharma companies. Asia Pacific is anticipated to be the fastest growing sarcoidosis therapeutics market owing to grants received from various international associations and rise in prevalence rate.


Like it? Share it!

Rohini Chaudhari

About the Author

Rohini Chaudhari
Joined: June 12th, 2019
Articles Posted: 205

More by this author